ULTRAPLACAD aims at the development of a novel robust in vitro diagnostic system for early cancer diagnosis, prognosis, patient follow-up and therapy efficacy assessment based on molecular analysis of peripheral blood (liquid biopsy). Although the platform may find wide applications in oncology, ULTRAPLACAD will focus solely on colorectal cancer (CRC) that is the second most frequently occurring cancer in the EU with an equal distribution among women and men. ULTRAPLACAD will provide unique and up to now not existing platform for the comprehensive detection of nucleic acids and protein CRC biomarkers in blood plasma. The extremely low concentration of most cancer biomarkers in blood imposes a stringent barrier to the wide applicability of the liquid biopsy for CRC diagnosis. The ULTRAPLACAD will deliver a disruptive diagnostic platform for the analysis of cancer biomarkers in blood plasma with unprecedented sensitivity and reliability. Reaching ULTRAPLACAD goals will significantly contribute to wider spread of diagnostic and prognostic protocols based on liquid biopsy – an emerging and rapidly developing cancer diagnostic approach. The use of innovative optical analytical techniques that take advantage of plasmonic metallic nanostructures (nanostructure-enhanced surface plasmon resonance imaging -NESPRI – and plasmonenhanced fluorescence spectroscopy imaging – PEFSI) will advance the state-of-art of CRC biomarkers detection (Figure 1).
Ultra sensitive plasmonic devices for early cancer diagnosis
Gambari R;Borgatti M;Zuccato C;Lampronti I;Finotti A
2015
Abstract
ULTRAPLACAD aims at the development of a novel robust in vitro diagnostic system for early cancer diagnosis, prognosis, patient follow-up and therapy efficacy assessment based on molecular analysis of peripheral blood (liquid biopsy). Although the platform may find wide applications in oncology, ULTRAPLACAD will focus solely on colorectal cancer (CRC) that is the second most frequently occurring cancer in the EU with an equal distribution among women and men. ULTRAPLACAD will provide unique and up to now not existing platform for the comprehensive detection of nucleic acids and protein CRC biomarkers in blood plasma. The extremely low concentration of most cancer biomarkers in blood imposes a stringent barrier to the wide applicability of the liquid biopsy for CRC diagnosis. The ULTRAPLACAD will deliver a disruptive diagnostic platform for the analysis of cancer biomarkers in blood plasma with unprecedented sensitivity and reliability. Reaching ULTRAPLACAD goals will significantly contribute to wider spread of diagnostic and prognostic protocols based on liquid biopsy – an emerging and rapidly developing cancer diagnostic approach. The use of innovative optical analytical techniques that take advantage of plasmonic metallic nanostructures (nanostructure-enhanced surface plasmon resonance imaging -NESPRI – and plasmonenhanced fluorescence spectroscopy imaging – PEFSI) will advance the state-of-art of CRC biomarkers detection (Figure 1).I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
